- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Anastrozole, Letrozole, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 20
- States / cities
- Chandler, Arizona • Springdale, Arkansas • Bakersfield, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 101
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypogonadism, Diabetes, Sarcopenia, Osteoporosis, Depression
- Interventions
- Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Placebo tablet, Placebo gel, Calcium Cardone 500mg with vitamin D 400 IU
- Drug · Dietary Supplement
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 65 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer
- Interventions
- Dovitinib, Aromatase Inhibitors
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Metastatic Breast Cancer
- Interventions
- IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more
- Conditions
- Obesity, Oligospermia
- Interventions
- Anastrozole, Placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 16 Years to 80 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Breast Cancer
- Interventions
- Tamoxifen, Anastrozole, Fulvestrant
- Drug
- Lead sponsor
- Priscilla McAuliffe
- Other
- Eligibility
- Female only
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Neoplasms, Breast Neoplasms
- Interventions
- Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 6
- States / cities
- Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor, Selective estrogen receptor modulator (SERM)
- Biological · Drug
- Lead sponsor
- Finn, Olivera, PhD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 176
- States / cities
- Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 139 more
- Conditions
- Breast Cancer
- Interventions
- Letrozole
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Elacestrant, Standard of Care
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 104
- States / cities
- Tucson, Arizona • Jonesboro, Arkansas • Fullerton, California + 84 more
- Conditions
- Breast Cancer, Breast Neoplasm
- Interventions
- Docetaxel - Dose A, Anastrozole, cyclophosphamide, Docetaxel - Dose B, Doxorubicin hydrochloride, Tamoxifen Citrate, Capecitabine - Dose B, Capecitabine - Dose A
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer
- Interventions
- Anastrozole
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Breast Cancer
- Interventions
- anastrozole, exemestane, letrozole, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Female only
- Enrollment
- 622 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Houston, Texas • Laredo, Texas
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, Early-Stage Breast Carcinoma
- Interventions
- Abemaciclib, Loperamide, Anastrozole
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 27
- States / cities
- Bakersfield, California • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer
- Interventions
- Onapristone ER, Onapristone ER + Anastrozole
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Hypogonadism
- Interventions
- anastrozole
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years and older · Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neoplasms, Breast
- Interventions
- Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs)
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 3
- States / cities
- Mobile, Alabama • Boston, Massachusetts • Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • Grass Valley, California + 43 more
- Conditions
- Metabolic Syndrome
- Interventions
- Zoladex, Testosterone gel, Anastrozole Pill, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 50 Years to 75 Years · Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Endometriosis
- Interventions
- Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 25
- States / cities
- San Diego, California • San Francisco, California • Gainesville, Florida + 22 more
- Conditions
- Solid Tumor, Advanced Breast Cancer
- Interventions
- Abemaciclib, Hydroxychloroquine 200 mg, Faslodex, Anastrazole, Letrozole, Hydroxychloroquine 400 mg, Hydroxychloroquine 600 mg
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more
- Conditions
- Breast Cancer
- Interventions
- anastrozole, tamoxifen citrate, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- Female only
- Enrollment
- 3,104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 724
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 499 more